Complementary and alternative medicine for major depressive disorder: A meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants

Journal of Clinical Psychiatry

Volumn 71, Issue 6, 2010, Pages 682-688

  Freeman, Marlene P ^a,b   Mischoulon, David ^a,b   Tedeschini, Enrico ^a   Goodness, Tracie ^a   Cohen, Lee S ^a,b   Fava, Maurizio ^a,b   Papakostas, George I ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DOCOSAHEXAENOIC ACID; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; OMEGA 3 FATTY ACID; PLACEBO; S ADENOSYLMETHIONINE; SERTRALINE;

ALTERNATIVE MEDICINE; ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; HYPERICUM PERFORATUM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; COMPLEMENTARY THERAPIES; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; S-ADENOSYLMETHIONINE; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953775769     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10r05976blu     Document Type: Article

References (33)

1. National Center for Complementary and Alternative Medicine, National Institutes of Health. What Is Complementary and Alternative Medicine? NCCAM Publication No. D156. Bethesda, MD: National Center for Complementary and Alternative Medicine; 2002.
2. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127.
3. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840- 1847.
4. Stolk P, Ten Berg MJ, Hemels ME, et al. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother. 2003;37(12):1891-1899.
5. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
6. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280(18):1569-1575.
7. Barnes PM, Bloom B, Nahin R. Complementary and Alternative Medicine Use Among Adults and Children: United States 2007. National Health Statistics Reports: No 12. Hyattsville, MD: National Center for Health Statistics; 2008.
8. Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry. 2001;158(2):289-294.
9. Druss BG, Rosenheck RA. Use of practitioner-based complementary therapies by persons reporting mental conditions in the United States. Arch Gen Psychiatry. 2000;57(7):708-714.
10. Simon GE, Cherkin DC, Sherman KJ, et al. Mental health visits to complementary and alternative medicine providers. Gen Hosp Psychiatry. 2004;26(3):171-177.
11. Elkins G, Rajab MH, Marcus J. Complementary and alternative medicine use by psychiatric inpatients. Psychol Rep. 2005;96(1):163-166. (Pubitemid 40405975)
12. Unützer J, Klap R, Sturm R, et al. Mental disorders and the use of alternative medicine: results from a national survey. Am J Psychiatry. 2000;157(11):1851-1857.
13. Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry. 2007;164(5):753-760.
14. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? a meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980:494.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987:xxix.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:xxvii.
18. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773-782.
19. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26(1):57-63.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
22. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Psychopharmacology Research Branch, National Institutes of Health; 1976:603.
23. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
24. Mackenzie ER, Taylor L, Bloom BS, et al. Ethnic minority use of complementary and alternative medicine (CAM): a national probability survey of CAM utilizers. Altern Ther Health Med. 2003;9(4):50-56.
25. Weissman MM, Leaf PJ, Holzer CE 3rd, et al. The epidemiology of depression: an update on sex differences in rates. J Affect Disord. 1984;7(3-4):179-188.
26. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978-1986.
27. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807-1814.
28. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):118-127.
29. Rutherford B, Sneed J, Devanand D, et al. Antidepressant study design affects patient expectancy: a pilot study. Psychol Med. 2010;40(5):781-788.
30. Dorn SD, Kaptchuk TJ, Park JB, et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil. 2007;19(8):630-637.
31. Yang H, Cusin C, Fava M. Is there a placebo problem in antidepressant trials? Curr Top Med Chem. 2005;5(11):1077-1086.
32. Kocsis JH, Leon AC, Markowitz JC, et al. Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry. 2009;70(3):354-361.
33. Miller FG, Emanuel EJ, Rosenstein DL, et al. Ethical issues concerning research in complementary and alternative medicine. JAMA. 2004;291(5):599-604.